Ignite Creation Date:
2024-05-06 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05690802
Status:
RECRUITING
Last Update Posted:
2023-01-19
First Post:
2023-01-10
Brief Title:
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
Sponsor:
Xijing Hospital
Organization:
Xijing Hospital
Study Overview
Official Title:
Palonosetron Hydrochloride Capsules Ruoshan Used to Prevent and Control Chemotherapy for Tumor Patients Real World Study on the Safety of Nausea and Vomiting Reduction
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TSEPHCC
Brief Summary:
To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy The characteristics of the applicable population clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed
Detailed Description:
At present as the mainstream antiemetics of CINV oral administration is the most commonly used method of drug therapy Clinical studies showed that there was no difference in the efficacy of 5-HT3 receptor antagonist between different administration routes oral and intravenous At the same time because the oral route is the most convenient oral preparations provide more and more convenient choices for clinicians and patients To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy The characteristics of the applicable population clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None